HWH International Inc.
ESYN Nasdaq Wholesale-Drugs, Proprietaries & Druggists' Sundries Financials FY2022βFY2025
What HWH International Inc. does
No business description yet.
- Legal name
- HWH International Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Mar 26, 2026
- Accession Β· CIK
- 0001493152-26-012738
0001897245
Revenue and margins
HWH International Inc. had $0.9M of revenue in fiscal 2025, down 30.8% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β$1.8M in fiscal 2025, β204.2% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
HWH International Inc. returned β to shareholders in fiscal 2025. The diluted share count rose 81.9%.
Balance sheet
Cash, debt and the ratios that show how comfortably HWH International Inc. can carry it.
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | $1.2M | $1.2M | $4.4M | $2.2M |
| Current ratio | 3.2x | 0.2x | 1.7x | 2.3x |
| Quick ratio | 3.2x | 0.2x | 1.7x | 2.3x |
| Total assets | $89.3M | $23.7M | $6.4M | $4.6M |
| Total liabilities | $3.4M | $27.3M | $3.6M | $1.9M |
| Shareholders' equity | β$2.0M | β$3.6M | $2.8M | $2.6M |
| Net debt (β = net cash) | β | β | β | β |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Net income is positive | β | β | β | β |
| Cash from operations is positive | β | β | β | β |
| Return on assets rose | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β |
| Debt fell relative to assets | β | β | β | β |
| Current ratio rose | β | β | β | β |
| Share count didn't rise | β | β | β | β |
| Gross margin rose | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β |
| F-score | β / 3 | β / 5 | β / 5 | 3 / 8 |
| Accruals ratio | 0.7% | 3.7% | β6.2% | β16.0% |
| Altman Z'' | β | β | β | β |
4 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | β | β | $1.3M | $0.9M |
| Gross profit | β | β | $0.6M | $0.5M |
| Interest expense | β | β | $0.1M | $0.1M |
| Pretax income | $0.3M | $1.0M | β$2.8M | β$2.6M |
| Income tax | $0.2M | $0.4M | β | $0.0M |
| Net income | $0.1M | $0.5M | β$2.8M | β$2.6M |
| Diluted EPS | β | β | β$0.76 | β$0.40 |
| Diluted shares | β | β | 0.00B | 0.01B |
| Cash flow | ||||
| Cash from operations | β$0.5M | β$1.5M | β$1.8M | β$1.8M |
| Capital expenditure | β | β | $0.0M | $0.0M |
| Free cash flow | β | β | β$1.8M | β$1.8M |
| Depreciation and amortization | β | β | $0.0M | $0.0M |
| Stock-based compensation | β | β | β | $1.6M |
| Share buybacks | β | $68.4M | $21.1M | β |
| Dividends and buybacks | β | $68.4M | $21.1M | β |
| Balance sheet | ||||
| Cash and short-term investments | $1.2M | $1.2M | $4.4M | $2.2M |
| Current assets | $1.2M | $1.3M | $5.5M | $3.0M |
| Current liabilities | $0.4M | $6.0M | $3.3M | $1.3M |
| Inventory | β | $0.0M | $0.0M | $0.0M |
| Property and equipment, net | β | $0.1M | $0.0M | $0.0M |
| Goodwill | β | β | $0.0M | $0.1M |
| Total assets | $89.3M | $23.7M | $6.4M | $4.6M |
| Total liabilities | $3.4M | $27.3M | $3.6M | $1.9M |
| Shareholders' equity | β$2.0M | β$3.6M | $2.8M | $2.6M |
| Margins | ||||
| Gross margin | β | β | 48.0% | 53.0% |
| Net margin | β | β | β219.4% | β303.4% |
| FCF margin | β | β | β147.6% | β204.2% |
| Returns | ||||
| Return on equity | β | β | β | β97.7% |
| Return on assets | 0.1% | 1.0% | β18.3% | β47.9% |
| Return on tangible equity | β | β | β99.4% | β105.1% |
| Growth | ||||
| Revenue growth | β | β | β | β30.8% |
| Net income growth | β | 383.6% | β601.0% | β |
| Share count change | β | β | β | 81.9% |
| Financial health | ||||
| Current ratio | 3.2x | 0.2x | 1.7x | 2.3x |
| Quick ratio | 3.2x | 0.2x | 1.7x | 2.3x |
| Capital allocation | ||||
| Capex / revenue | β | β | 2.4% | 2.2% |
| Stock comp / revenue | β | β | β | 182.3% |
| Quality scores | ||||
| Piotroski F-score | β | β | β | 3.0 |
| Accruals ratio | 0.7% | 3.7% | β6.2% | β16.0% |
Source: SEC EDGAR XBRL filings (CIK 0001897245). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.